Passage BIO (PASG) Capital Expenditures (2019 - 2024)
Passage BIO (PASG) posted quarterly Capital Expenditures of $14000.0 for Q4 2024, up 7.69% year-over-year from $13000.0 in Q1 2024, and up 7.69% quarter-over-quarter from $13000.0 in Q4 2023.
Passage BIO (PASG) Capital Expenditures (2019 - 2024) Analysis & Trends
Passage BIO's Capital Expenditures history runs 6 years deep, the most recent figure standing at $14000.0 for Q4 2024.
- In Q4 2024, Capital Expenditures rose 7.69% year-over-year to $14000.0; the TTM figure through Dec 2024 stood at $134000.0 (down 8.22% YoY), while the FY2024 annual figure was $34000.0, down 76.71% from the prior year.
- Capital Expenditures for Q4 2024 stood at $14000.0, up from $13000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $6.8 million in Q4 2021, with the low at $4000.0 in Q3 2023.
- The 5-year median for Capital Expenditures is $244000.0 (2022), against an average of $1.2 million.
- The sharpest annual moves came in 2021 and 2023: Capital Expenditures surged 4165.96% in 2021, then tumbled 98.36% in 2023.
- Passage BIO's Capital Expenditures stood at $804000.0 in 2020, then soared by 748.13% to $6.8 million in 2021, then slumped by 93.05% to $474000.0 in 2022, then slumped by 97.26% to $13000.0 in 2023, then rose by 7.69% to $14000.0 in 2024.
- Business Quant data shows PASG's Capital Expenditures at $14000.0 in Q4 2024, $13000.0 in Q4 2023, and $4000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 14,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 103,000.00 |
| Jun 30, 2023 | 103,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Dec 31, 2022 | 474,000.00 |
| Dec 31, 2022 | 474,000.00 |
| Sep 30, 2022 | 244,000.00 |
| Sep 30, 2022 | 244,000.00 |
| Jun 30, 2022 | 831,000.00 |
| Jun 30, 2022 | 831,000.00 |
| Mar 31, 2022 | 725,000.00 |
| Mar 31, 2022 | 725,000.00 |
| Dec 31, 2021 | 6.82 Mn |
| Dec 31, 2021 | 6.82 Mn |